Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599082 | 0.67 | SMN1; SMN2 (0.46) | SMN1; SMN2GLAKMT2AL3MBTL1 | |
| SCHEMBL14564594 | 0.67 | — | — | |
| SCHEMBL5489748 | 0.66 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1 | |
| SCHEMBL20936054 | 0.66 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1 | |
| SCHEMBL4253446 | 0.66 | SMN1; SMN2 (0.53) | SMN1; SMN2GLAKMT2AL3MBTL1 | |
| SCHEMBL19102433 | 0.66 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1 | |
| SCHEMBL12345773 | 0.65 | — | — | |
| SCHEMBL14564595 | 0.64 | — | — | |
| SCHEMBL12499138 | 0.61 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1 | |
| SCHEMBL15329364 | 0.61 | SMN1; SMN2 (0.41) | SMN1; SMN2GLAKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | CEDARS-SINAI MEDICAL CENTER (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | PARP1, PARP2, PARP11 | SMN1; SMN2 1471/4885GLA 2323/4885KMT2A 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.